Mark Marex, Senior Specialist, Index Research & Development at Nasdaq Investment Intelligence, Rene Reyna, Head of Thematic & Specialty Product Strategy ETFs and Indexed Strategies at Invesco and Brian Mueller, Executive Vice President, Chief Financial Officer at BioMarin discuss the evolving biotech landscape and key drivers for growth and performance in 2022.
The Nasdaq Biotechnology Index (NBI) offers a rules-based, cap-weighted benchmark for one of the fasting growing sectors in tech. NBI captures hundreds of Nasdaq-listed biotech and pharmaceutical companies and its modified cap-weighted approach ensures that top industry leaders and most influential players in biotech are weighted accordingly.
In June of 2021, Nasdaq and Invesco partnered to launch the Invesco Nasdaq Biotechnology ETF (IBBQ), which tracks the underlying investment results of the Nasdaq Biotechnology Index and aims provide investors with access to innovative companies shaping the biotech landscape. While Biotech has caught widespread attention due to its role in curbing the pandemic, it represents a wide scope of technologies beyond vaccines, including therapeutics and genomics. Top holdings include Amgen (AMGN), Illumina (ILMN), Moderna (MRNA), and Biogen (BIIB).
To learn more, register & watch Nasdaq’s webcast: Biotech’s Post-Covid Future: What’s Next For the Innovators of the Nasdaq Biotechnology Index?
Learn what drove biotech performance in the pivotal year of 2021, and why having the proper benchmark for this unique industry is more important than ever. Along with a special guest from Nasdaq-listed BioMarin Pharmaceutical, take a deep dive into some of the cutting-edge innovation happening within the space, especially as it relates to gene therapy for the treatment of rare diseases. More broadly, place the incredible achievements to tame Covid-19 into the proper context of biotech’s next stage of evolution, as an array of technological advancements begin to accelerate our understanding and treatment of illness.